Search


Discussing the FIREFLY-1 pediatric low-grade glioma data with Day One Bio at #ASCO23
Day One Bio CEO Jeremy Bender describes tovorafenib FIREFLY-1 trial result and Day One’s Plan to seek an accelerated approval for the drug.
Jun 5, 2023
Also look for unique social pages for BiotechTV U.
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.